An investigation on behalf of former and current employees of Repros Therapeutics, Inc. (Public, NASDAQ: RPRX) concerning potential Employee Retirement Income Security Act (ERISA) Breach of Fiduciary Duty was announced.

Repros Therapeutics, Inc. has been accused of securities fraud and according to a an investigation by a law firm under ERISA employees (former and current) of Repros Therapeutics, Inc. (Public, NASDAQ: RPRX) may be eligible to file a ERISA complaint for putting stock options at risk if they can prove their employer violated its fiduciary duty to them. The Fiduciary duty refers to a companys responsibility to the people who invest in it and if an employer puts the companys interest ahead of the investors, it has broken its fiduciary duty, so the investigation.

Repros Therapeutics, Inc. faces a securities class action lawsuit over alleged violations of Federal Securities Laws on behalf of purchasers of the common stock of Repros Therapeutics, Inc. (NASDAQ: RPRX) common stock from July 1, 2009 through August 3, 2009. An investor filed a proposed securities class action lawsuit in the United States District Court for the Southern District of Texas against Repros Therapeutics and others alleging violations of Federal Securities Laws. According to the complaint the plaintiff alleges that Repros Therapeutics and certain of its officers violated Section 10(b) and 20(a) of the Securities Exchange Act of 1934 by issuing between July 1, 2009 through August 3, 2009 misleading statements concerning the adverse events that patients suffered in clinical trials for Repros Therapeutics lead drug candidate Proellex. According to a press release by the law firm the complaint alleges that when Repros Therapeutics disclosed the truth concerning the seriousness of the adverse events, its stock price dropped, damaging investors.

On August 3, 2009 Repros Therapeutics announced that it was suspending all further dosing of Proellex in their clinical trials as a result of serious adverse events. The August 3rd announcement disclosed that the adverse events were more frequent and more serious than Repros Therapeutics had previously reported, so the investigation. As a result of this news, Repros Therapeutics 's stock (NASDAQ: RPRX) fell over 70%. Repros Therapeutics Inc., located in The Woodlands, Texas, is a development-stage biopharmaceutical company focused on the development of oral small molecule drugs for unmet medical needs.

Repros Therapeutics principal drug, Proellex, is a selective blocker of the progesterone receptor and is being developed for the treatment of uterine fibroids, anemia associated with excessive menstrual bleeding relating to uterine fibroids, or anemia associated with uterine fibroids and endometriosis. Repros Therapeutics Inc. (NASDAQ: RPRX) reported in 2007 Total Revenue of $1.51million and in 2008 Total Revenue of $0.43million. Shares of Repros Therapeutics Inc. (NASDAQ: RPRX) traded recently at $1.27 per share, down from a 52weekHigh of $13.94 per share and $14.56 per share in 2007.